Modality
Degrader
MOA
RAS(ON)i
Target
KRASG12D
Pathway
Hedgehog
PBCBCCGastric Ca
Development Pipeline
Preclinical
Oct 2018
→ Jan 2028
PreclinicalCurrent
NCT06100134
2,442 pts·Gastric Ca
2018-10→2028-01·Not yet recruiting
2,442 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-231.8y awayInterim· Gastric Ca
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
Preclinical
Not yet…
Catalysts
Interim
2028-01-23 · 1.8y away
Gastric Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06100134 | Preclinical | Gastric Ca | Not yet recr... | 2442 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR |